Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacopsychiatry

• Publication date

  2015-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0035-1565070PMID 26506574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study

  2015cited by this paper
• Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

  2015cited by this paper
• Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

  2015cited by this paper
• AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

  2014cited by this paper
• Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

  2013cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

  2013cited by this paper
• Olanzapine: A Systematic Review and Meta-Regression of the Relationships Between Dose, Plasma Concentration, Receptor Occupancy, and Response

  2013cited by this paper
• Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

  2013cited by this paper
• Predicting Plasma Concentration of Risperidone Associated With Dosage Change: A Population Pharmacokinetic Study

  2012cited by this paper
• Dopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis

  2011cited by this paper
• Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

  2011cited by this paper
• Plasma Olanzapine in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1999-2009

  2011cited by this paper
• Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study

  2011cited by this paper
• Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs: A Systematic Review and Pooled Analysis

  2011cited by this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cited by this paper
• Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking

  2010cited by this paper
• Patterns of Antipsychotic Medication Use in Australia 2002–2007

  2010cited by this paper
• Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study

  2009cited by this paper
• Predicting Age‐Specific Dosing of Antipsychotics

  2009cited by this paper
• Drug Prescription Patterns in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund

  2009cited by this paper
• Atypical antipsychotic drugs and the risk of sudden cardiac death.

  2009cited by this paper
• Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.

  2009cited by this paper
• Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study

  2008cited by this paper
• Sex, Race, and Smoking Impact Olanzapine Exposure

  2008influential reference
• Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan.

  2008cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.

  2007cited by this paper
• A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.

  2007cited by this paper
• Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors—a PET study in schizophrenia

  2006cited by this paper
• A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.

  2006cited by this paper
• Clinical outcome and olanzapine plasma levels in acute schizophrenia

  2005cited by this paper
• Investigation of Target Plasma Concentration-Effect Relationships for Olanzapine in Schizophrenia

  2003cited by this paper
• Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.

  2002cited by this paper
• Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

  2000influential reference
• Olanzapine. Pharmacokinetic and pharmacodynamic profile.

  1999cited by this paper
• A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

  1998cited by this paper
• Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.

  1995cited by this paper
• Positron Emission Tomography Studies on D2 and 5‐HT2 Receptor Binding in Risperidone‐Treated Schizophrenic Patients

  1995influential reference
• Some suggestions for measuring predictive performance

  1981cited by this paper
• Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

  1977cited by this paper
• Malta

  1913cited by this paper

• Pharmacokinetics

  2021cites this paper
• Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model

  2021cites this paper
• Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial.

  2019cites this paper
• Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology.

  2019cites this paper
• The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data

  2019cites this paper
• The effects of illness severity , cognition , and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia : An analysis of clinical antipsychotics trials of intervention effectiveness ( CATIE ) data

  2018cites this paper
• Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.

  2016cites this paper